have different pharmacologic profiles, they were examined separately. Results: Forty participants started study medication; 14 participants terminated prematurely. Donepeziltreated participants experienced a 14-point greater improvement in the FIM-motor score compared to either galantamine-treated participants or the historical comparator group (repeated measures mixed model, group ! time interaction p ! 0.0001). Change in apathy, but not in cognition, was also associated with change in the FIM-motor score.
Introduction
Impairments in cognition [1] and motivation [2] are common after stroke and predict poor functional recovery [3] [4] [5] . We propose that pharmacological agents that enhance cognition and/or diminish apathy may, when combined with traditional rehabilitative efforts, lead to improved functional recovery. Acetylcholinesterase inhibitors (AchEi) are candidate agents based on studies demonstrating that AchEi: (1) have cognitive benefit in vascular dementia, Alzheimer's disease with comorbid cerebrovascular disease [6] [7] [8] , and delirium concurrent with vascular dementia [9] , and (2) can work acutely, improving attention within hours of the first oral dose [10] . AchEi also have antiapathy effects in dementia [11] , consistent with the evidence that apathy is the result of decreased cholinergic innervation [12] .
For this pilot study, we hypothesized that the use of donepezil or galantamine in patients with acute poststroke cognitive impairment would be feasible and associated with superior rehabilitation outcomes compared to a historical group of stroke patients. We also explored changes in cognition and apathy and compared the two AchEi, given their different pharmacologic profiles.
Methods
Participants were recruited from three inpatient rehabilitation units at the University of Pittsburgh Medical Center. Written informed consent was obtained in accordance with the University Institutional Review Board's procedures. Inclusion criteria were: aged 6 60 years; ischemic stroke within the last 30 days, and cognitive impairment (either of new onset or markedly worse since stroke, as reported by the subject and their family). Participants were included if they scored at least 1 standard deviation below age-matched norms on the Hopkins Verbal Learning Test for memory [13] , Digit Span summary score from the Wechsler Adult Intelligence Test for attention [14] or Executive Interview [15] for executive function. Exclusion criteria were: previous diagnosis of Alzheimer's disease based on a clinical evaluation by the investigators (E.M.W. and E.J.L.) that included reports from the patient, family and primary care provider as needed; prestroke or current treatment with an AchEi or memantine; aphasia or behavioral impairments prohibiting study assessments; current major depressive episode, psychosis or mania, and substance/alcohol abuse within the last 3 months.
Participants were assigned to donepezil (n = 20) or galantamine (n = 20) in an order determined by study drug availability. Galantamine was dosed at 4 mg twice a day (b.i.d.) for 4 weeks, then 8 mg b.i.d. for 4 weeks, and then 12 mg b.i.d. for 4 weeks. Donepezil was dosed at 5 mg/day for 6 weeks and then at 10 mg/ day for 6 weeks. Doses were decreased or titration delayed if side effects emerged.
Participants were assessed with the Functional Independence Measure (FIM TM ) [16] and the Apathy Evaluation Scale [17] at baseline, week 2 (or discharge from inpatient rehabilitation) and week 12. A prestroke FIM, reflecting the participant's disability level prior to the index stroke, was obtained. The FIM rater was blinded to study medication assignment. Only the 13 motor items of the FIM (FIM-motor) [18] were used in statistical analyses as other, more sensitive, instruments were used to assess mood and cognition. The Hopkins Verbal Learning Test, Digit Span, and Executive Interview were repeated at 12 weeks by a rater who was not blinded to study medication assignment. A side effect checklist was used to score the 11 most common AchEi side effects from 0 (absent) to 3 (severe) for each symptom. Brain-imaging studies conducted for routine clinical management were reviewed for stroke location.
A historical comparison group was derived via chart review of all elderly ischemic stroke survivors admitted to the UPMC Rehabilitation Hospital (the main recruitment site for this study) between January 29, 1996, and December 22, 1999. The historical comparator group (n = 110) was created by group-matching the historical patients to study participants, sequentially, by FIM-motor score at admission, age and length of inpatient rehabilitation.
Data Analysis
The donepezil and galantamine groups were examined separately due to the drugs' different pharmacologic profiles. The baseline demographic and clinical characteristics for the 3 groups (galantamine, donepezil and historical comparator) were compared using analysis of variance (ANOVA) for continuous variables and using Fisher's exact test for categorical data. Appropriate transformations were used for nonnormally distributed continuous variables.
Side effects, cognition, apathy and FIM-motor scores for the 2 AchEi groups were analyzed using a repeated measures mixed model to examine group, time and group ! time interactions. An unstructured variance-covariance matrix was used. Due to the different variances in FIM-motor scores, the residual matrix was allowed to have different variances for each group in the FIM-motor model [19] . Separate mixed models for the FIM-motor scores were also run, controlling for cognition and apathy individually. The mixed models for FIM-motor scores were repeated with the 3 groups using the same assumptions on the variance-covariance matrix.
Results
From February 25, 2003, to January 27, 2005, 314 elderly ischemic stroke survivors were admitted for inpatient rehabilitation. Sixty-seven patients consented to this study, 20 were subsequently excluded in accordance with the protocol, and 7 refused to start study medication. Thus, 40 participants started study medication.
Study Dropouts
Fourteen participants (7 receiving donepezil, 7 on galantamine) dropped out prior to week 12. At baseline, dropouts were older, more likely to be female and more disabled but did not differ on race, prestroke functional ability, length of rehabilitation hospitalization, or days between stroke and rehabilitation admission compared to the study completers (data not shown). Reasons for dropping out included: gastrointestinal side effects (n = 5); concurrent medical problems (n = 3); new onset agitation (n = 1); withdrawal of consent (n = 4), and subject relocation (n = 1).
Study Completers and Historical Comparator Group
Study completers and the historical comparator group did not differ on baseline demographic and clinical characteristics ( table 1 ). Only 9 of 13 galantamine study completers achieved the target dose (24 mg/day), because of tolerability issues, whereas all 13 donepezil study completers achieved the target dose (10 mg/day). Side effect checklist scores did not differ between the 2 groups over time (data not shown). 1 Natural log transformation used in the analyses. 2 Natural log (X + 0.1) transformation used in the analyses. 3 Fisher's exact test. 4 Reflects the participants' disability level prior to the index stroke as estimated by a structured interview with participants and their families. 5 
Functional Outcomes

Discussion
To our knowledge this is the first study to examine AchEi for promoting functional recovery after stroke when combined with inpatient rehabilitation. Participants who received donepezil had a more successful rehabilitation outcome than either the galantamine participants or the historical comparator group -a notable finding given the small number of participants. As lower FIM scores correlate with greater need for caregiver assistance [20] , the larger FIM improvement in the donepezil group may clinically translate into a need for less hands-on care.
While this early result is intriguing, there are several study limitations, including: (1) the lack of a concurrent placebo control group, (2) the small number of participants, and (3) the lack of randomization or blinding. However, drug assignment was unrelated to any participant characteristics, and the FIM rater was blind to drug assignment. Furthermore, the small number of galantamine subjects completing the study at the target dose of galantamine (relative to the number of donepezil subjects who achieved the target dose) limits our ability to compare the efficacy of these 2 drugs. However, this limitation does not undermine the real-world significance of our result that subjects randomized to donepezil tolerated the study medication and performed better on FIMmotor at week 12 compared to the historical comparator group. Notwithstanding these limitations, our finding provides preliminary support for the feasibility of using AchEi in post-stroke cognitively impaired elders undergoing inpatient rehabilitation. The study drugs were generally well tolerated, consistent with findings in vascular dementia [11] [12] [13] .
AchEi may lead to improved rehabilitation outcomes through several possible pathways. First, AchEi may acutely enhance cognitive function, thereby increasing a patient's ability to learn during rehabilitation. Second, they may reduce apathy, thereby leading a patient to be a more 'motivated' participant in rehabilitation. Third, they may lead to greater activation of the motor cortex and perhaps enhance motor cortex reorganization after stroke [21] . The latter possibility is supported by a small randomized controlled trial in which participants with significant residual upper-limb paresis 1 year after stroke demonstrated a trend towards superior motor improvement when constraint-induced therapy was combined with donepezil [22] . The observed difference in functional improvement between donepezil and galantamine participants may reflect the drugs' different pharmacokinetic profiles. In placebo-controlled trials for Alzheimer's disease, donepezil [23] but not galantamine [24] demonstrated efficacy at the starting dose, suggesting that donepezil can penetrate the blood-brain barrier at lower doses.
In summary, this pilot study suggests that donepezil is safe and fairly well tolerated by cognitively impaired elderly stroke patients and, when combined with inpatient rehabilitation, may lead to improved functional outcomes. A randomized trial by our group is underway to establish donepezil's efficacy in promoting functional recovery in the immediate post-stroke period and to clarify the mechanism by which it leads to improved functional recovery.
